Elite Pharmaceuticals Inc. has reported significant financial results for the fiscal year ended March 31, 2025. The company's total revenues saw an impressive increase of $27.4 million, or 48%, reaching $84.0 million compared to $56.6 million in the previous year. This substantial growth was primarily driven by four product launches during the current fiscal year, alongside boosted sales from the Elite Label product line. Manufacturing fees revenue experienced a notable rise of $27.9 million, or 51%, compared to the previous year, largely due to the same factors contributing to the overall revenue growth. In contrast, licensing fees revenue saw a decline of $0.4 million, or 18%, as the company shifted away from licensing products to third parties. On the expenses front, research and development costs increased by $1.1 million, or 16%, totaling $8.0 million, while general and administrative expenses rose by $1.9 million, or 26%, amounting to $9.0 million. The company did not provide outlook or guidance for future periods in the report.